4Vote!
Business Wire (Free subscription) | 5 hours ago
CARLSBAD, Calif.--(BUSINESS WIRE)--Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), unveiled plans for an educational webinar about microRNA biology that will highlight several recent exciting discoveries in the field and showcase the therapeutic strategies based on microRNA. The webinar, scheduled for 3:00 p.m....
+Vote!
Xconomy (Free subscription) | 5 hours ago
... Nobel Laureate and Caltech biology professor, and John Maraganore , the CEO of Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: ALNY ), a leader in the emerging field of RNA interference treatments. While those speakers can talk about what they see happening around the world in biotech, we will also feature some of the most exciting local companies that are making their names on the...
3Vote!
Xconomy (Free subscription) | 12/03/2009
A handful of startups from the Boston area are joining an exclusive club today. The World Economic Forum—the Swiss nonprofit that has previously honored such companies as Cambridge, MA-based biotech Alnylam Pharmaceuticals (NASDAQ:ALNY), PayPal, and Google (NASDAQ:GOOG)—has named six local companies to its prestigious annual list of Technology Pioneers, the organization announced...
3Vote!
Xconomy (Free subscription) | 12/02/2009
... drug-maker Merck KGaA and Whitehouse Station, NJ-based Merck & Co. (NYSE: MRK ), though. — Alnylam Pharmaceuticals CEO John Maraganore chatted with Luke about his rather unconventional philosophy on how to make decisions in biotech. Two key steps, according to Maraganore: ditch the spreadsheets, trust the science. —Cambridge-based Forma Therapeutics nabbed $25.5 million in a Series B venture...
